Customize your JAMA Network experience by selecting one or more topics from the list below.
In the Viewpoint entitled “Evolving Issues in the Treatment of Depression”1 published in the June 25, 2019, issue of JAMA, clarification was needed regarding the use of the terms “ketamine” and “esketamine.” In the section titled “Ketamine,” the first sentence of the first paragraph should have read “On March 5, 2019, the Food and Drug Administration approved nasal esketamine (the s-enantiomer of ketamine) (Spravato), in conjunction with an oral antidepressant in adults, as a drug for treatment-resistant depression (TRD).” The first sentence in the third paragraph of that section should have read “Clinical trials have established that more than half of the patients with TRD experience antidepressant effect of intranasal ketamine and esketamine or intravenous ketamine in addition to their treatment as usual.” And the third sentence of the third paragraph in that same section should have read “Ketamine and esketamine represent promising drugs that potentially can help alleviate TRD, but further studies are necessary to identify which patients will receive sustained benefit.” This article was corrected online.
Clarifying Terminology Use. JAMA. 2019;322(19):1925. doi:10.1001/jama.2019.17982
Create a personal account or sign in to: